See also

References

1. ^Johnson MP, Baez M, Jagdmann GE, Britton TC, Large TH, Callagaro DO, et al. (July 2003). "Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine".Journal of Medicinal Chemistry.46 (15):3189–92.doi:10.1021/jm034015u.PMID 12852748.
2. ^Schaffhauser H, Rowe BA, Morales S, Chavez-Noriega LE, Yin R, Jachec C, et al. (October 2003). "Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2".Molecular Pharmacology.64 (4):798–810.doi:10.1124/mol.64.4.798.PMID 14500736.S2CID 15919973.
3. ^Poisik O, Raju DV, Verreault M, Rodriguez A, Abeniyi OA, Conn PJ, Smith Y (2005). "Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus".Neuropharmacology.49 (Suppl 1):57–69.doi:10.1016/j.neuropharm.2005.03.006.PMID 15993439.S2CID 21881395.
4. ^Galici R, Echemendia NG, Rodriguez AL, Conn PJ (December 2005)."A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity"(PDF).The Journal of Pharmacology and Experimental Therapeutics.315 (3):1181–1187.doi:10.1124/jpet.105.091074.PMID 16123306.S2CID 9159875. Archived fromthe original(PDF) on 2019-02-21.
5. ^Marino MJ, Conn PJ (February 2006). "Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors".Current Opinion in Pharmacology.6 (1):98–102.doi:10.1016/j.coph.2005.09.006.PMID 16368268.
6. ^Harich S, Gross G, Bespalov A (July 2007). "Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment".Psychopharmacology.192 (4):511–9.doi:10.1007/s00213-007-0742-y.PMID 17318501.S2CID 7551116.
7. ^Conn PJ, Jones CK (January 2009)."Promise of mGluR2/3 activators in psychiatry".Neuropsychopharmacology.34 (1):248–9.doi:10.1038/npp.2008.156.PMC 2907744.PMID 19079073.
8. ^Hermes ML, Renaud LP (March 2011)."Postsynaptic and presynaptic group II metabotropic glutamate receptor activation reduces neuronal excitability in rat midline paraventricular thalamic nucleus"(PDF).The Journal of Pharmacology and Experimental Therapeutics.336 (3):840–9.doi:10.1124/jpet.110.176149.PMID 21139059.S2CID 25111011. Archived fromthe original(PDF) on 2019-02-22.